🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Pramod Bhattarai!🔬 Dr. Bhattarai serves rural and underserved communities and his research focuses on health disparities, particularly in people living with HIV. 🧫 When out of the clinic, he enjoys coin collecting 🪙 and hiking 🥾!
09.12.2025 16:12 — 👍 1 🔁 1 💬 0 📌 0
Systemic Corticosteroids, Mortality, and Infections in Pneumonia and Acute Respiratory Distress Syndrome : A Systematic Review and Meta-analysis - PubMed
None. (PROSPERO: CRD42024536301).
Soulmate et al.’s meta-analysis showed, with moderate certainty of evidence, that adjunctive low-dose, short-course corticosteroids probably reduce short-term mortality in both severe PNA and ARDS.
pubmed.ncbi.nlm.nih.gov/41325621/
03.12.2025 16:53 — 👍 0 🔁 0 💬 0 📌 0
📢📢📢Less than a week left! Learn the latest on HIV-associated lung disease in the upcoming 🌲PINE Webinar on #worldaidsday December 1st! @idsainfo.bsky.social @atscommunity.bsky.social @btsrespiratory.bsky.social @theunion.org
Sign up here: thoracic.zoom.us/webinar/regi...
27.11.2025 02:37 — 👍 1 🔁 0 💬 0 📌 0
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia publications.ersnet.org/content/erj/...
18.11.2025 15:12 — 👍 3 🔁 1 💬 1 📌 0
European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.
🚨 New 2025 ERS guidelines for the management of adult bronchiectasis! Takeaway:
Recommend to offer long-term macrolides to patients at high risk of exacerbations. High-risk features include P. aeruginosa infection, COPD, PCD, RA, and sputum purulence.
doi.org/10.1183/1399...
18.11.2025 02:09 — 👍 0 🔁 0 💬 0 📌 0
European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.
🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key takeaway:
Recommend not offering long-term ICS to patients with bronchiectasis who do not have coexisting asthma or COPD.
doi.org/10.1183/1399...
14.11.2025 21:46 — 👍 0 🔁 0 💬 0 📌 0
Welcome! You are invited to join a webinar: Pulmonary Infections Network of Experts: A Case of HIV-Associated Lung Disease. After registering, you will receive a confirmation email about joining the w...
Josalyn Cho, MD, University of Iowa, and Neelima Navuluri, MD, MPH, Duke University, will be discussing a case of HIV-associated lung disease to mark World AIDS Day, presented by Jonah Kreniske, MD, o...
🔥Mark your calendars!🔥
@ATS_PITB
is hosting a🌲PINE🌲Webinar on HIV-associated lung disease 🫁 Case-based discussion, with🌍global experts!
📅 Monday, December 1st 3PM ET
🗒️Register Here: thoracic.zoom.us/webinar/regi...
#TB @ATS_Assemblies
@IDSAInfo
@TheUnion_TBLH
@BTSrespiratory
13.11.2025 01:41 — 👍 0 🔁 0 💬 0 📌 1
European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.
🚨New 2025 ERS guidelines for the management of adult bronchiectasis! Key update:
Recommend offering long‑term inhaled antibiotics to patients at high risk of exacerbations and with chronic Pseudomonas aeruginosa infection despite standard care.
publications.ersnet.org/content/erj/...
12.11.2025 21:54 — 👍 0 🔁 0 💬 0 📌 0
⏰Only a few hours left to submit abstracts and case reports for #ATS2026! ⏰
The ATS is accepting scientific abstracts and case reports on all aspects of respiratory disease, critical care, and sleep medicine for ATS 2026.
Deadline is 5 p.m. ET, Nov. 5, 2025: conference.thoracic.org/program/call...
05.11.2025 15:00 — 👍 3 🔁 3 💬 0 📌 0
New #IDSAGuidelines! IDSA has released updated evidence-based recommendations on administering age-appropriate Influenza and RSV vaccinations in populations with compromised immunity. https://www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/
04.11.2025 22:13 — 👍 7 🔁 5 💬 0 📌 6
European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
BackgroundBronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.MethodsA European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist, and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction, and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of 8 PICO (Patient, Intervention, Comparator, Outcomes) questions and 3 narrative questions were developed.RecommendationsThe Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations, and managing the deteriorating patient.ConclusionThe ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.Scope and objectivesThe European Respiratory Society (ERS) guidelines for the management of bronchiectasis in adults provide evidence-based recommendations for the care of people with clinically significant bronchiectasis, defined by the presence of permanent dilatation of the bronchi evident on chest CT scan, along with characteristic clinical symptoms. [1] These guidelines are intended for all healthcare professionals involved in the care of adults with bronchiectasis, as well as for policymakers, regulatory authorities, and pharmaceutical companies. Bronchiectasis is a complex and heterogeneous disease; therefore, no guideline can be entirely comprehensive or replace clinical judgement. All guideline recommendations must be interpreted within the specific clinical context in which they are applied. Separate ERS guidelines for the management of bronchiectasis in children exist [2]. Bronchiectasis due to cystic fibrosis (CF) has a distinct evidence base; therefore, guidance for the management of CF is provided elsewhere. [3] Some bronchiectasis-associated conditions also have distinct guidelines for investigation and management, such as primary ciliary dyskinesia (PCD) [4], allergic bronchopulmonary aspergillosis (ABPA) [5] and non-tuberculous mycobacterial (NTM) pulmonary disease [6]. While the present guidelines apply for these conditions, they should be interpreted in conjunction with the relevant syndrome-specific recommendations.
🔥🔥🔥 Hot of the press: European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis publications.ersnet.org/content/erj/... #Bronchiectasis @atscommunity.bsky.social @btsrespiratory.bsky.social
03.11.2025 23:05 — 👍 2 🔁 0 💬 0 📌 0
🧪Meet our @ATS_PITB Assembly Early Career Highlight, Dr. Kevin Guzman!🔬 Dr. Guzman is working to improve outcomes in people living with HIV and TB. 🧫
24.10.2025 14:58 — 👍 0 🔁 0 💬 0 📌 0
Presenter: Mansi Chaturvedi, MD (Univ. of Maryland/NIH)
Moderator: Jerry Zifodya, MD, MPH, TM (Tulane)
Experts: Celso Khosa, PhD (Instituto Nacional de Saúde) & Brian Allwood, MD (Stellenbosch Univ/Tygerberg Hospital, South Africa)
26.09.2025 19:16 — 👍 0 🔁 0 💬 0 📌 0
🔥Mark your calendars!🔥
@ats-pitb.bsky.social is hosting a🌲PINE🌲Webinar on Post-TB Lung Disease 🫁
Case-based discussion, diagnosis & treatment with 🌍 global experts!
📅 Tue Oct 28 10AM ET
🗒️Register Here: bit.ly/47X6auu
#TB @atscommunity.bsky.social @theunion.org @btsrespiratory.bsky.social
26.09.2025 19:16 — 👍 4 🔁 2 💬 1 📌 0
Great honor to welcome Dr. Charles Dela Cruz, past @ats-pitb.bsky.social Chair, to @tulanemedicine.bsky.social today! He is giving an outstanding talk on COVID-19 and interferons—sharing deep insights into pathogenesis and host responses. #COVID19 #Interferons #ATS
24.09.2025 17:37 — 👍 3 🔁 1 💬 1 📌 0
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, c...
The shortened BDLC strategy was not non-inferior to the control. Accumulating evidence
suggests that this patient population might require longer, reinforced regimens.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial - The Lancet Respiratory Medicine www.thelancet.com/journals/lan...
24.09.2025 17:20 — 👍 2 🔁 0 💬 0 📌 0
Research Priorities for Noninvasive Sampling of the Lower Respiratory Tract during Acute Respiratory Failure: An Official American Thoracic Society Workshop Report | Annals of the American Thoracic Society
🚨 ATS Workshop Report on non-invasive sampling of the lower respiratory tract: Experts highlight how to tailor your testing and make non-invasive testing fast, reproducible, and scalable. #PulmCCM #ATSworkshop buff.ly/i2qobaA
01.09.2025 02:36 — 👍 2 🔁 0 💬 0 📌 0
Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine | Articles in P...
🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key change:
Empiric antibiotics are suggested for adults hospitalized with clinical and imaging evidence of CAP—whether non-severe or severe—who test positive for a respiratory virus.
doi.org/10.1164/rccm...
29.08.2025 18:05 — 👍 1 🔁 0 💬 0 📌 0
📣Calling all assembly members!📣 Help shape the future of the ATS by nominating a colleague for a leadership position within your assembly. We're accepting nominations for a variety of positions!
Submit your nominations before Sept. 4! surveymonkey.com/r/YHQFMGZ
28.08.2025 12:46 — 👍 0 🔁 1 💬 0 📌 0
Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine | Articles in P...
🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key points:
For stable adults with outpatient CAP, <5 days of antibiotics are recommended (minimum duration: 3 days).
Systemic corticosteroids for adults hospitalized with severe CAP.
doi.org/10.1164/rccm...
26.08.2025 17:03 — 👍 2 🔁 1 💬 0 📌 0
Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial | American Journal of Respiratory and Critical Care M...
AJRCCM: Results from a randomized, placebo-controlled Phase II clinical trial evaluating the optimal dose, acceptable safety, and tolerability of levofloxacin as part of a multidrug TB regimen.
doi.org/10.1164/rccm...
25.08.2025 18:58 — 👍 0 🔁 0 💬 0 📌 0
Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine | Articles in P...
🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key changes:
Lung ultrasound now an evidence-based alternative to chest X-ray for diagnosis
No antibiotics for outpatients with no comorbidities and a positive viral test
doi.org/10.1164/rccm...
22.08.2025 14:08 — 👍 0 🔁 0 💬 0 📌 0
👋 Welcome to ERS Assembly 10 – Respiratory Infections!
We focus on all aspects of pulmonary infections through 3 active groups.
Science, education & collaboration.
#ERS_A10 #Assembly10
Keeping #medicalstudents, #residents, #fellows, & #earlycareerprofessionals up to date on the latest news in #PCCM
The International Union Against Tuberculosis and Lung Disease is a global scientific organisation working to #EndTB and improve #lunghealth. #NoTobacco #CleanAir.
Welcome to the official account of the ATS Assembly on Respiratory Structure and Function (RSF)!
🫁 Welcome to the account of #Respiratory Projects & Events of Lena Group. We support research & education in #RespiratoryDiseases #Bronchiectasis #RareDiseases
https://lenagroup.net/
PCCM fellow @Columbia 🫁 | Former Chief Resident and alum @UMiami |
Interested in transplant and health equity
ATS Assembly on pulmonary patient care/education/research/QI
ILD, COPD, CF, IP, surgery, bronchiectasis, transplant, PFTs + more
🫁 & ICU doctor | director, inpatient medicine & critical care @partnersinhealth.bsky.social | he/him | opinions my own
ID doc at University of Florida COM. HIV medicine, epidemiology, global health. Cooking aficionado, cat enthusiastic, aspiring karaoke singer.
Candidate Advanced Nurse Practitioner in Respiratory Care. Interested in Chronic Respiratory and Renal nursing and medicine, politics, science, science fiction and entertainment. Married with 3 boys and a dog. Climate conscious. Be an organ donor🙏.🇮🇪🇪🇺
Lung microbiome researcher, infectious disease clinician, parent, bike commuter, and snow-lover in Minneapolis. Views my own, not my employer's.
Pulmonary and critical care fellow @YalePCCSM | Formerly @UPMC @ColumbiaPS @RescueOrg @Epicentre_MSF @GHP_HarvardChan @haverfordedu
MD-PhD student at Indiana University & Purdue BME | Pienaar Computational Systems Pharmacology Lab | Mechanistic modeling of nontuberculous mycobacteria lung disease | IU alum | Views mine
Pulm/crit doc - sleep and control of breathing nerd.
Ya no más vergüenza al pedalear... ningún obstáculo me podrá frenar... tengo un nuevo concepto de felicidad... alcancé mi equilibrio espiritual🎼F.T,31M.🚵🏾♂⛹️🏃🌳🏞️🌊🌬️⛈️☀️🌎🐶🐕🐺🐘🦇🦦🦉🐜🐝🐞👩❤️👨
🫁 Filière de santé des maladies respiratoires rares hébergée à l'hôpital Bicêtre (AP-HP)
🌐 respifil.fr
📧 https://respifil.fr/nous-contacter/
Pulmonary Physician-Scientist 🫁,
Professor of Medicine 🩺,
Seeker of Adventures 🧗🏻🚵🏻♂️🏔️.
COPD, Sleep, HIV, EBM.
Opinions are my own.
Program Manager ID/TB/HIV/Cancer/Rare Diseases, US & International Research Projects
💃🏽🐶🐈⬛📸🌳🌹🌅☕️🍷📖✍🏼💻🩻🇲🇽🇺🇸
PCCSMP at UC San Diego Health #UCSDHealth. Our #PCCM fellowship is committed to training academic leaders & providing world class care, education, and research.
